Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis
Ziqian Peng, Kirsty Hodgson, Matthew Fisher, Shenglin Mei, Margarita Orozco‐Moreno, Lizhi Cao, Michael C. Kemp, Wayne Gatlin, Louisa Donald, Feier Zeng, Michelle Anne Lawson, Dániel Ungár, David B. Sykes, David J. Elliott, Li Peng, , Jennifer Munkley
This study identifies Siglec-engaging sialoglycans as upregulated in prostate cancer and shows they can be targeted to suppress bone metastasis using a bisialidase.
bioRxiv · Nov 12, 2025 · PreprintCancer Biology